TLDR
- Codexis (CDXS) exceeded Q4 EPS expectations by $0.10, posting $0.11 against a $0.01 analyst consensus
- Fourth-quarter revenue reached $38.9 million, representing an 81% year-over-year increase and surpassing the $35.83 million forecast
- A Technology Transfer Agreement worth $37.8 million with Merck powered the Q4 revenue jump
- Annual net loss for 2025 improved to $44.0 million compared to $65.3 million in 2024
- Company projects 2026 revenue between $72–$76 million; available cash extends operations through 2027
On March 11, 2026, Codexis unveiled its fourth-quarter and complete 2025 fiscal year earnings, surpassing analyst projections on both profit and revenue metrics. Shares responded positively, advancing 2.4% to reach $1.27.
The company delivered fourth-quarter earnings per share of $0.11, exceeding the Street’s $0.01 expectation by $0.10. Quarterly revenue totaled $38.9 million, beating estimates of $35.83 million and representing an 81% surge from the $21.5 million recorded in Q4 2024.
The primary catalyst was a Technology Transfer Agreement valued at $37.8 million with pharmaceutical giant Merck, which concluded during the fourth quarter. This substantial transaction significantly influenced the period’s financial performance.
Annual revenue increased 19% to $70.4 million, advancing from the previous year’s $59.3 million. The company’s product gross margin showed improvement, reaching 64% versus 56% in the prior period.
The annual net loss contracted to $44.0 million ($0.50 per share) from a $65.3 million deficit ($0.89 per share) in 2024. Notably, Q4 delivered profitability with net income of $9.6 million, contrasting sharply with the $10.4 million loss recorded in the same quarter last year.
Selling, general and administrative expenses decreased to $47.1 million annually from $55.1 million in 2024, benefiting from reduced stock-based compensation and legal costs. Research and development investment increased to $52.3 million from $46.3 million.
The fiscal year also absorbed $3.4 million in one-time restructuring expenses related to a workforce reduction implemented in November 2025.
Cash Position and Guidance
Codexis closed 2025 with $78.2 million in cash, cash equivalents and short-term investments. Management indicates this liquidity provides adequate funding through year-end 2027.
For fiscal 2026, the organization projects total revenues ranging from $72 million to $76 million.
Regarding business development, Codexis is currently working with more than 40 companies across 55 prospective opportunities. CEO Alison Moore highlighted that discussions have evolved from initial feasibility assessments toward more comprehensive contractual negotiations.
The organization secured a lease for a GMP facility with kilogram-scale manufacturing capabilities. Renovation work is scheduled to commence in the latter half of 2026, with complete operational capacity expected by the conclusion of 2027.
Codexis additionally established a partnership with Axolabs—marking its third CDMO collaboration—to assess its ECO Synthesis technology at Axolabs’ production facilities.
Analyst Sentiment and Institutional Activity
Notwithstanding the earnings outperformance, analyst perspectives remain cautious. Weiss Ratings maintained a “Sell” recommendation on January 21, while MarketBeat’s consensus rating also registers as “Sell.”
Shares currently trade nearer to the 52-week low of $0.96 than the high of $3.87, with market capitalization standing at $114.7 million. The 50-day moving average rests at $1.39, while the 200-day average is positioned at $1.90.
Institutional investors have demonstrated increased interest. Millennium Management expanded its holdings by 3,376.5% during Q3. Renaissance Technologies increased its position by 137.5% in Q4. Collectively, institutional ownership represents 78.54% of outstanding shares.
The company aims to secure a licensing agreement with a major pharmaceutical partner during the second half of 2026 and intends to showcase stereoisomer control data at the 2026 TIDES USA annual conference.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
